About Coral Genomics
Coral Genomics is a company based in San Francisco (United States) founded in 2018. Coral Genomics has raised $150 thousand across 3 funding rounds from investors including HHS and Y Combinator. The company has 1 employees as of December 31, 2022. Coral Genomics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Atrys, among others.
- Headquarter San Francisco, United States
- Employees 1 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$150 K (USD)
in 3 rounds
-
Latest Funding Round
$1.62 M (USD), Grant
Feb 01, 2021
-
Investors
HHS
& 1 more
-
Employee Count
1
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Coral Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Coral Genomics
Coral Genomics has successfully raised a total of $150K across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.62 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Coral Genomics
Coral Genomics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Coral Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Coral Genomics
Investment portfolio details for Coral Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Coral Genomics
Detailed financials for Coral Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Coral Genomics Comparisons
Peer comparison for Coral Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Coral Genomics
Coral Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Atrys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of diagnostic and therapeutic services catering to cancer
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Coral Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Coral Genomics
Complete news archive for Coral Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Coral Genomics
Coral Genomics was founded in 2018.
Coral Genomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Coral Genomics is a funded company, having raised a total of $150K across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Coral Genomics is 1.
Coral Genomics was founded in 2018 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where genomic data is leveraged to streamline drug development processes. Analysis of patient tolerance to drug formulations is conducted to enable personalized treatments. Services include data-driven optimization for pharmaceutical applications, supporting targeted drug creation based on individual genetic profiles.
Coral Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Coral Genomics has 2 investors. Key investors include HHS, and Y Combinator.